Clinical Study PotentialPositive TETON study data is expected to expand Tyvaso to a larger market.
Revenue GrowthTyvaso DPI, a dry powder inhaler that delivers treprostinil for PAH and pulmonary hypertension associated with interstitial lung disease (PH-ILD), is on track to exceed $1B in FY24 annual net revenue, less than three years after FDA approval.
Technological ValidationTwo FDA approvals in diabetes and pulmonary arterial hypertension (PAH) have validated MannKind's technology platform in transforming therapeutics with proven efficacy into inhaled formulation to improve dosing convenience while maintaining or even improving treatment outcomes.